01
Never beyond the trial
No generated dose exceeds the maximum studied in the reference trial. An even more conservative ceiling is applied by default depending on profile.
Method & Sources
Every line of your protocol cites its source.
incretide invents nothing. Titration schedules, dose ceilings, trajectory ranges and decision rules all come from published clinical trials and established recommendations — listed in full below.
Our four generation rules
02
Ranges, never promises
Trajectories are orders of magnitude derived from published curves, always presented as such.
03
Tolerance decides
Three questions at every step. A single "no" means 4 more weeks at the same dose.
04
Caution by default
When in doubt, the document recommends slowing down and talking to a doctor.
How the dose is decided, in detail
We are not doctors: the dose is your decision, on your own or with a healthcare professional. What we do, and what we do not do:
- Incretide sets no dose: we show you, using published data, what your profile corresponds to in existing clinical trials;
- each trial card shows its titration schedule exactly as published, with no adaptation on our side;
- the dose is then your decision, on your own or with a healthcare professional: it alone builds your tracking document.
We are not doctors and we cannot tell you which dose to take. Your tracking document is built solely from the dose you entered ; it is restated in your protocol and your PDF, along with its history.
References cited, in full
Each card shows exactly what incretide uses from the reference — no more, no less.
TRIUMPHNON APPROUVÉE
Retatrutide — TRIUMPH program design
Giblin MJ et al. — Design of the phase 3 TRIUMPH program. Diabetes, Obesity and Metabolism, 2026.
What incretide uses from it
- Structure of the phase 3 program’s titration steps.
TRIUMPHNON APPROUVÉE
Retatrutide — TRIUMPH-1 topline results
Eli Lilly and Company — TRIUMPH-1 topline results. Press release, May 21, 2026.
What incretide uses from it
- Orders of magnitude for phase 3 efficacy (presented as announced results).
TRIUMPHNON APPROUVÉE
Retatrutide — phase 2
Jastreboff AM et al. — Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023.
What incretide uses from it
- Schedule 2 → 4 → 6 → 9 → 12 mg in 4-week steps.
- Weight-loss ranges (up to −24.2% at 48 weeks at 12 mg, population average).
- Maximum dose: 12 mg/week.
SURMOUNT
Tirzepatide — SURMOUNT-1
Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
What incretide uses from it
- Starting at 2.5 mg, increased by 2.5 mg every 4 weeks, maximum 15 mg/week.
- Orders of magnitude: −20.9% at 72 weeks at 15 mg, population average.
STEP
Semaglutide — STEP-1
Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine, 2021.
What incretide uses from it
- Starting at 0.25 mg, 4-week steps, maximum 2.4 mg/week.
- Orders of magnitude: −14.9% at 68 weeks, population average.
NUTRITION
Nutrition — protein in a calorie deficit
Established recommendations. Reference literature in sports and clinical nutrition.
What incretide uses from it
- Personalised daily protein target: 1.6 to 2.2 g protein/kg/day to preserve lean mass in a calorie deficit.
References are provided for transparency. incretide is not affiliated with any of the authors, journals or laboratories cited.
Regulatory status
As of the time of writing. This table determines what your document can — and cannot — say.
Retatrutide
NON APPROUVÉETRIUMPH (phase 3)
Not approved in any country to date
Schedule from a clinical trial protocol; reminder on every page of the PDF.
Tirzepatide
SURMOUNTSURMOUNT-1
Approved in several countries (obesity)
Trial titration schedule; prescription and follow-up by a doctor.
Semaglutide
STEPSTEP-1
Approved in several countries (obesity)
Trial titration schedule; prescription and follow-up by a doctor.
What incretide is not
- incretide is not a medical device and provides no individualised medical advice.
- Trial data describe population averages, not your personal case.
- The document prescribes nothing: any treatment decision belongs to a doctor.
- GLP-1/GIP/glucagon agonist treatments have contraindications and side effects: read the stop signals in your protocol.
Data confidentiality
All data entered (profile, weight, check-ins) is calculated and stored locally in your browser. No health data is sent to a server in this version. JSON export and full deletion are available in My tracking.